Venture Capital

Pioneers
Innovation-Focused
Unique Access

venture-capital
98
Active Companies with
$1B Enterprise Value
(as of 9/30/25)
11
Years of Delivering 2x+ TVPI at
the Portfolio Company Level*

Platform Investment Criteria

Technology
Life Science
Industry
Series A/Seed
Stage
90% US
/
10% Int’l
Geographical Focus

*Total Value to Paid-In Capital (“TVPI”) represents the ratio of the current value of investments within the Fund, plus the total value of all distributions relative to a limited partner’s capital contribution.

Targeting Opportunity

Venture’s Power Law illustrates that a very small number of venture investments generate the vast majority of returns. That’s why we believe access to strong investors, early ownership and portfolio construction are critical.

The Venture Capital team, has built enduring relationships across the venture landscape, providing the team with unique access to top-tier investors. These venture capital investors are often out of reach of most limited partners. The team’s investment philosophy is predicated on their conviction in elite managers and the team’s experience identifying the next generation of top venture capital talent.


Creating Value

Talent

Accessing top-tier managers who fund what we believe are the best founders building dominant teams

Portfolio Construction

Built-in vintage and sector diversification

Evergreen & Secondary Expertise

Deep secondary underwriting expertise and sourcing access

Team Members

Paul_Gompers
Paul Gompers*

Co-Founder and Advisor

Matt_Horten
Matt Horten*

Managing Director

Teri_Hightower
Teri Hightower

Director

Aletha_Shipman
Aletha Shipman

Senior Accountant

Brooke_Remple
Brooke Remple

Accountant

Cassie_Walters
Cassie Walters

Associate, Investor Relations

Jeremy_Held
Jeremy Held*

Managing Director, Evergreen Strategies

* Investment Committee member

Portfolio

While the list below is certainly not exhaustive, these portfolio companies are representative of the top 15% of outcomes that drive 75% of total value for our investors.

Acadia Pharmaceuticals
Advance Intelligence
Affini-T Therapeutics
Affirm
Airbnb
Allakos
Amunix Pharmaceuticals
Anduril
Artbio
Artera
Athletic Media
Bitcoin
Cargo Therapeutics
Carmot Therapeutics
Carta
Cato Networks
Cerebras Systems
Chinook Therapeutics
Circle
Clasp Therapeutics
ClickUp
Coinbase Global
Constellation Pharmaceuticals
Contego Medical
Cue Health
Demandbase
Doximity
EQRx
EXACT Sciences
Eightfold AI
Eikon Therapeutics
Ele.me
Enliven Therapeuctics
Epsagon
Exonics Therapeutics
Facebook
Faire Wholesale
Flexus Biosciences
Forma AI
Frore Systems
Ganji
Gupshup
Gusto
HashiCorp
HilleVax
IVERIC bio
Imago Biosciences
Immunovant
Inari Medical
JFrog
Lengo Therapeutics
Lyft
Mark43
Marqeta
Medable
Multicoin
Nasuni Corporation
Navan
Nu Holdings
NuVia
Oculus VR
Omada Health
One Finance
OpenAI
Orum
Outreach
Palantir Technologies
Pinecone Systems
Plaid
Postmates
Primary Kids
Qunar.com
Ramp
Reata Pharmaceuticals
Relay Therapeutics
Revolution Medicines
Route
Rubrik
Sage Therapeutics
Slack
SmartRecruiters
Snap
Solana
Sourcegraph
SpaceX
Square
Standard Bariatrics
Strava
Stripe
Synnovation Therapeutics
Talkdesk
ThoughtSpot
Tools for Humanity
Trillium Therapeutics
Twitter
Ultima Genomics
Upstart Holdings
Vectivbio
Volterra
Workrise
Xenon Pharmaceuticals
XiaoHongShu
Zenput
Zumper
eToro